Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".  

The Advisory Board selected a record number of 144 high-quality abstracts. Professor Sava Micic (Belgrade, RS), chairman of the meeting: "The challenging scientific programme is filled with a variety of subjects, such as - on Friday morning - bladder cancer, followed by the debate 'Urinary diversion at cystectomy: Continent is the way to go'".

In the afternoon, the focus is on Andrology with lectures about, among other things, the treatment of male infertility (S. Micic). Prof N Sofikitis, Ioannina (GR) tries to answer the question 'Who needs testosterone substitution and how?' Professor Chris Chapple (Sheffield, GB) is responsible for this year's State-of-the-Art lecture on 'Have we solved the problem of anterior urethral stricture disease?'  

Paediatric urology is extensively covered with several lectures on Saturday morning, as well as the panel debate 'Are we overdiagnosing prostate cancer?' chaired by Prof Chapple.                                     

Poster viewing sessions provide excellent chances for younger urologists to profile themselves and display their abstracts. This year the topics are Bladder cancer and urinary diversion, BPH and prostate biopsy, incontinence and overactive bladder, Testicular cancer, infertility, erectile dysfunction, Kidney cancer, Prostate cancer and, on Saturday morning, Stone disease, Trauma and reconstruction and Miscellaneous.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Single drug compound may offer a promising new strategy for treating prostate cancer patients